NurExone Biologic targets US market expansion and investor outreach

NurExone Biologic Inc. is preparing for a strategic presentation at the Moody Capital Solutions Disruptive Growth & Life Sciences Conference in New York on September 9 and 10. Co-founder and Chairman Yoram Drucker will present the company’s vision for treating spinal cord injuries to investors and participate in one-on-one meetings.

The company is also advancing its financial position. On August 21, NurExone completed a private placement of nearly two million units, raising gross proceeds of over one million Canadian dollars. This capital is intended to support ongoing development, specifically the transition from preclinical results to clinical testing of ExoPTEN.

To facilitate a future listing on a major US exchange, NurExone has scheduled an extraordinary general meeting for September 15. Shareholders will vote on a reverse stock split of up to 30:1, a move designed to meet minimum price requirements and increase visibility and liquidity in the American market.